NOV-2018 : Bernard Vrijens, CEO of AARDEX, is an invited speaker at the 2nd value added medicines conference, Brussels, November 21, 2018
This event is organized by Medicines for Europe about ” an innovative approach for patients’ future”.

NOV-2018 : Bernard Vrijens, CEO of AARDEX, is an invited speaker at the 2nd value added medicines conference, Brussels, November 21, 2018
This event is organized by Medicines for Europe about ” an innovative approach for patients’ future”.
Clinical trials rely on accurate data. But what if one of the most important variables whether a patient actually takes the medication is based on guesswork? Traditional methods like pill counts, diaries, or verbal confirmation have long been the standard,
Imagine spending years developing a promising new treatment, only to have its potential clouded by something as simple (and as overlooked) as whether or not people actually took their pills. This isn’t just a small glitch in the process. In